Patients with lichen sclerosus experience moderate satisfaction with treatment and impairment of quality of life: results of a cross-sectional study

Cranenburgh, O.D. van; Nijland, S.B.W.; Lindeboom, Robert; Korte, J. de; Rie, Menno A. de; Stege, Jacqueline A. ter; Prinsen, Cecilia A.C.

doi:10.1111/bjd.15125

Cited by 33 publications

(36 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies found that patients reported treatment effectiveness as the most important factor for overall treatment satisfaction. 2,22,23 The group using systemic treatment presented significantly higher satisfaction scores with regard to the "effectiveness," compared with the group without systemic treatment. The "global satisfaction" was significantly higher for alitretinoin, ciclosporin, and dupilumab compared with nonsystemic treatments.…”

Section: Discussionmentioning

confidence: 94%

“…This implies that effectiveness of treatment is the major factor affecting “global satisfaction,” which is supported by previous studies on, for example, patients with psoriasis and lichen sclerosis. These studies found that patients reported treatment effectiveness as the most important factor for overall treatment satisfaction . The group using systemic treatment presented significantly higher satisfaction scores with regard to the “effectiveness,” compared with the group without systemic treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life, treatment satisfaction, and adherence to treatment in patients with vesicular hand eczema: A cross‐sectional study

et al. 2020

View full text Add to dashboard Cite

Background Recurrent vesicular hand eczema frequently has a chronic course and needs long‐term treatment. Objectives To evaluate health‐related quality of life (HRQoL), treatment satisfaction, and adherence in patients with vesicular hand eczema. Methods Patients using one main treatment for at least three months were included. Data on HRQoL (Quality of Life in Hand Eczema Questionnaire [QOLHEQ]), treatment satisfaction (Treatment Satisfaction Questionnaire for Medication, version II), and treatment adherence (4‐item Morisky Medication Adherence Scale) were collected. Univariate and multivariate regression analysis were used to predict variables associated with HRQoL. Results HRQoL was moderately impaired, with the highest impact in the QOLHEQ subdomain symptoms. Female sex, more severe hand eczema, and lower treatment satisfaction were associated with more impairment in HRQoL. Patients with severe/very severe hand eczema had significant lower “global satisfaction” scores compared with the other severity groups. The “global satisfaction” and treatment adherence in patients using systemic treatment were significantly higher compared with those with only topical treatment. Conclusions In patients with vesicular hand eczema disease severity affects both HRQoL and treatment satisfaction. Systemic treatment of severe hand eczema could improve the severity and as a result also HRQoL, treatment satisfaction, and medication adherence.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Quality of life, treatment satisfaction, and adherence to treatment in patients with vesicular hand eczema: A cross‐sectional study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As a result, a relevant part of the patients labelled as responders are not actually clear of the disease, and this may account for a divergence between physicians' and patients' perspectives regarding treatment outcome and satisfaction. 11…”

Section: Discussionmentioning

confidence: 99%

Clearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera?

Borghi

Virgili

Minghetti

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Current data, probably underestimated, suggest a prevalence in the general population of 0.1–4% for cutaneous LP (2), 1.27–2.0% for oral LP (3), and 0.1–3.3% for LS (4). Few authors investigated the association between these conditions and thyroid diseases and, even fewer, the possible common etiopathogenic mechanism(s).…”

Section: Introductionmentioning

confidence: 90%

Thyroid Autoimmunity and Lichen

et al. 2017

View full text Add to dashboard Cite

Lichen planus (LP) and lichen sclerosus (LS) are cutaneous-mucous diseases with uncertain epidemiology. Current data, which are likely to be underestimated, suggest a prevalence in the general population of 0.1–4% for cutaneous LP, 1.27–2.0% for oral LP, and 0.1–3.3% for LS. While etiology of lichen is still unknown, clinical and histological evidence show an (auto)immune pathogenesis. Association of lichen with autoimmune thyroid disease (AITD) has been investigated in few studies. This association appears better defined in the case of LS, while is more controversial for LP. In both situations, the frequency of the association is higher in females. We review the available literature on the correlation between the different types of lichen and AITD, and the literature on the genetic risk factors which are shared by both conditions. Such data suggest that a common pathogenic mechanism could be the cause for co-occurrence of lichen and AITD, at least in some patients. Additionally, analyzing literature data and in continuity with our previous work on other autoimmune diseases, we suggest that molecular mimicry could trigger both diseases, and thus explain their co-occurrence.

show abstract

Patients with lichen sclerosus experience moderate satisfaction with treatment and impairment of quality of life: results of a cross-sectional study

Cited by 33 publications

References 57 publications

Quality of life, treatment satisfaction, and adherence to treatment in patients with vesicular hand eczema: A cross‐sectional study

Quality of life, treatment satisfaction, and adherence to treatment in patients with vesicular hand eczema: A cross‐sectional study

Clearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera?

Thyroid Autoimmunity and Lichen

Contact Info

Product

Resources

About